Xuede Lin, Ph.D. - Publications

Affiliations: 
2008 University of Nebraska Medical Center, Omaha, NE, United States 
Area:
Immunology

4 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2009 Lin X, Wang X, Capek HL, Simone LC, Tuli A, Morris CR, Reber AJ, Solheim JC. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines. Cancer Immunology, Immunotherapy : Cii. 58: 729-36. PMID 18828016 DOI: 10.1007/S00262-008-0595-1  0.599
2007 Ashour AE, Lin X, Wang X, Turnquist HR, Burns NM, Tuli A, Sadanandam A, Suleiman K, Singh RK, Talmadge JE, Solheim JC. CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biology & Therapy. 6: 1206-10. PMID 17617742 DOI: 10.4161/Cbt.6.8.4405  0.62
2007 Ashour AE, Turnquist HR, Burns N, Wang X, Lin X, Tremayne J, Hollingsworth MA, Blonder JM, Rosenthal GJ, Talmadge JE, Solheim JC. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. Cancer Biotherapy & Radiopharmaceuticals. 22: 235-8. PMID 17600470 DOI: 10.1089/Cbr.2007.336  0.685
2007 Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, Solheim JC. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. International Journal of Oncology. 30: 631-9. PMID 17273764 DOI: 10.3892/Ijo.30.3.631  0.709
Show low-probability matches.